Singapore has suspended the sales of Bextra, an anti-inflammatory drug produced by the global pharmaceutical manufacturer Pfizer.
Study shows that taking Bextra may pose risk to patients’ cardiovascular safety or incur rare but serious skin reactions, which have led to similar bans on the drug in the United States, the European Union and Canada.
The Health Sciences Authority (HSA) of Singapore confirmed thatno local case of serious skin reactions had been reported, but it advised patients taking the drug to consult their doctors for alternative treatments.
Commonly used to treat osteoarthritis or rheumatoid arthritis, Bextra has entered Singapore market since May 2003 to deal with acute pain, the report said. Enditem